Summary: WearLinq has acquired AMI Cardiac Monitoring, enhancing its capability to offer clinical services nationwide. This acquisition will expand access to WearLinq’s FDA-cleared eWave 6-lead ECG monitor, combining advanced technology with AMI’s clinical expertise to improve cardiac diagnostics and patient outcomes.

Key Takeaways:

  • Strategic Acquisition: WearLinq’s acquisition of AMI Cardiac Monitoring will enhance its clinical service capacity across the U.S.
  • Advanced ECG Monitoring: The eWave 6-lead ECG device provides detailed cardiac monitoring, improving diagnostic accuracy.

WearLinq, provider of wearable health monitoring and diagnosis solutions, announced the acquisition of AMI Cardiac Monitoring, an independent diagnostic testing facility (IDTF) with more than 33 years of expertise in ambulatory cardiac monitoring.

AMI Cardiac Monitoring Acquisition

This strategic acquisition aims to boost WearLinq’s capacity to offer clinical services across all 50 states and provide more patients access to its eWave 6-lead wearable ECG monitor, which recently received FDA 510(k) clearance.

“The astute clinical capabilities of AMI combined with the advanced technology of WearLinq will create a tremendously productive partnership,” said Konrad Morzkowski, CEO of WearLinq. “AMI and WearLinq share the same values and visions of providing excellent services for patients and clinical facilities. This synergy enhances our ability to deliver comprehensive cardiac diagnostics, promising significant advancements in healthcare services for cardiac patients and will undoubtedly position us as market leaders very soon.”

WearLinq Advanced Technology Integration

The eWave 6-lead ECG device provides cardiologists with a detailed, multidimensional view of the heart, offering P-wave visibility and ECG clarity. It works with the patient’s smartphone, allowing for long-term monitoring with recharging in an AirPods-like case and magnetically attaches to WearLinq’s skin-like (patent pending) adhesive patches.

“We are excited to join forces with WearLinq, a company at the forefront of cardiac monitoring innovation. This partnership aligns perfectly with our mission to provide exceptional diagnostic services,” said Dorothy Glodek, founder of AMI Cardiac Monitoring. “By integrating WearLinq’s advanced 6-lead ECG technology with our extensive clinical expertise, we can offer unparalleled cardiac care to patients nationwide. Together, we are set to revolutionize the field of ambulatory cardiac monitoring, ensuring more accurate diagnoses and improved patient outcomes.”

Patient-Centered Design

Designed with patient comfort and clinical accuracy in mind, the WearLinq ECG device is wearable and minimally intrusive. It allows patients to maintain their lifestyle while continuously monitoring their cardiac health. Integrated with a cloud platform, the device ensures near real-time data analysis and actionable insights for healthcare providers.